S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
NASDAQ:PCSA

Processa Pharmaceuticals - PCSA News Today

$0.90
+0.05 (+5.88%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.85
$0.94
50-Day Range
$0.86
$2.04
52-Week Range
$0.80
$4.52
Volume
25,551 shs
Average Volume
44,546 shs
Market Capitalization
$14.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Get Processa Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter.



PCSA Media Mentions By Week

PCSA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PCSA
News Sentiment

0.00

0.69

Average
Medical
News Sentiment

PCSA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PCSA Articles
This Week

0

0

PCSA Articles
Average Week

SourceHeadline
finance.yahoo.com logoProcessa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023.
finance.yahoo.com - January 4 at 10:18 AM
marketwatch.com logoProcessa Pharmaceuticals Stock Climbs on Latest Data from Gastroparesis Study
marketwatch.com - December 15 at 3:27 PM
finance.yahoo.com logoProcessa Pharma's Investigational Candidate Improves Gastroparesis-Associated Clinical Symptoms
finance.yahoo.com - December 14 at 3:52 PM
msn.com logoProcessa jumps 11% after mid-stage data for gastroparesis candidate
msn.com - December 14 at 10:52 AM
finance.yahoo.com logoProcessa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial
finance.yahoo.com - December 14 at 10:52 AM
seekingalpha.com logoProcessa Pharmaceuticals, Inc. (PCSA) Q3 2022 Earnings Call Transcript
seekingalpha.com - November 13 at 1:40 AM
finance.yahoo.com logoProcessa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - November 8 at 6:22 PM
finance.yahoo.com logoPCS12852 Improves Gastric Emptying in Gastroparesis Patients
finance.yahoo.com - November 8 at 1:21 PM
msn.com logoEarnings Preview: Processa Pharmaceuticals
msn.com - November 7 at 8:15 PM
finance.yahoo.com logoProcessa Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2022 Results and Provide Drug Development Update on November 8, 2022 at 4:30 p.m. EST
finance.yahoo.com - November 2 at 5:50 PM
finance.yahoo.com logoProcessa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial
finance.yahoo.com - November 1 at 5:24 PM
finance.yahoo.com logoProcessa Pharmaceuticals Provides Update on Enrollment Across all Clinical Programs
finance.yahoo.com - September 15 at 8:44 AM
finance.yahoo.com logoProcessa Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 12-14, 2022
finance.yahoo.com - September 7 at 10:58 AM
finance.yahoo.com logoProcessa Pharmaceuticals Appoints Khoso Baluch and James Neal to its Board of Directors and Justin Yorke to Chairman of the Board
finance.yahoo.com - August 16 at 11:51 AM
seekingalpha.com logoProcessa Pharmaceuticals, Inc. (PCSA) CEO David Young on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com - August 14 at 9:34 AM
finance.yahoo.com logoProcessa Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update
finance.yahoo.com - August 12 at 12:20 PM
marketwatch.com logoInvestorNewsBreaks - Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Q2 2022 Results Conference Call
marketwatch.com - August 10 at 10:42 AM
finance.yahoo.com logoProcessa Pharmaceuticals to Host Conference Call to Discuss Its Second Quarter 2022 Results and Provide 2nd Half Clinical Pipeline Update on August 11, 2022, at 4:30 p.m. EST
finance.yahoo.com - August 5 at 6:09 PM
finance.yahoo.com logoProcessa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499
finance.yahoo.com - August 4 at 11:23 AM
finance.yahoo.com logoProcessa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499
finance.yahoo.com - August 3 at 8:47 PM
nasdaq.com logoProcessa Pharmaceuticals Rings the Closing Bell
nasdaq.com - July 12 at 11:47 PM
finance.yahoo.com logoProcessa Pharmaceuticals to Present at the World Orphan Drug Congress USA, July 11-13, 2022
finance.yahoo.com - July 12 at 8:54 AM
finance.yahoo.com logoHere's Why We're Watching Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Situation
finance.yahoo.com - June 24 at 9:36 AM
seekingalpha.com logoPCSA Processa Pharmaceuticals, Inc.
seekingalpha.com - June 18 at 10:26 PM
nasdaq.com logoBuying Power of Bitcoin vs. Processa Pharmaceuticals at New 52-Week High
nasdaq.com - May 16 at 1:16 PM
seekingalpha.com logoProcessa Pharmaceuticals Non-GAAP EPS of -$0.20
seekingalpha.com - May 14 at 6:57 PM
seekingalpha.com logoProcessa Pharmaceuticals' (PCSA) CEO David Young on Q1 2022 Results - Earnings Call Transcript
seekingalpha.com - May 14 at 6:57 PM
finance.yahoo.com logoProcessa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
finance.yahoo.com - May 13 at 1:26 AM
finance.yahoo.com logoProcessa Pharmaceuticals to Host Conference Call to Discuss First Quarter 2022 Results and Provide Drug Development Update on May 12, 2022 at 4:30 p.m. EST
finance.yahoo.com - May 5 at 11:10 AM
seekingalpha.com logoProcessa begins dosing in phase 1b trial of chemotherapy combo for gastrointestinal cancer
seekingalpha.com - April 20 at 3:16 PM
finance.yahoo.com logoProcessa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine)
finance.yahoo.com - April 20 at 10:13 AM
benzinga.com logoProcessa Pharmaceuticals Announces First Patient Enrolled In PCS12852 Phase 2a Trial For The Treatment Of Gastroparesis
benzinga.com - April 5 at 10:56 AM
finance.yahoo.com logoProcessa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis
finance.yahoo.com - April 5 at 10:56 AM
seekingalpha.com logoProcessa Pharmaceuticals GAAP EPS of -$0.75 misses by $0.01
seekingalpha.com - March 30 at 6:39 PM
finance.yahoo.com logoProcessa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. EST
finance.yahoo.com - March 23 at 12:39 PM
finance.yahoo.com logoProcessa Pharmaceuticals CEO Dr. David Young To Present at the Oppenheimer 32nd Annual Healthcare Conference
finance.yahoo.com - March 10 at 9:09 AM
nasdaq.com logoA number of insiders bought Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) stock last year, which is great news for shareholders
nasdaq.com - February 1 at 1:36 PM
finance.yahoo.com logoProcessa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022
finance.yahoo.com - January 26 at 10:19 AM
finance.yahoo.com logoMultiple insiders bought Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) stock earlier this year, a positive sign for shareholders
finance.yahoo.com - January 17 at 5:06 PM
nasdaq.com logoProcessa Pharmaceuticals, Inc. Common Stock (PCSA)
nasdaq.com - January 13 at 7:40 PM
finance.yahoo.com logoProcessa Pharmaceuticals Announces Third Quarter 2021 Results and Provides Corporate Update
finance.yahoo.com - November 11 at 7:48 PM
nasdaq.com logoWhat You Need To Know About Processa Pharmaceuticals, Inc.'s (NASDAQ:PCSA) Investor Composition
nasdaq.com - November 2 at 1:59 AM
finance.yahoo.com logoProcessa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on November 11 at 5:30 p.m. EST
finance.yahoo.com - October 26 at 9:02 AM
finance.yahoo.com logoWhat Kind Of Shareholders Hold The Majority In Processa Pharmaceuticals, Inc.'s (NASDAQ:PCSA) Shares?
finance.yahoo.com - October 19 at 2:15 PM
finance.yahoo.com logoProcessa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of Gastroparesis
finance.yahoo.com - October 12 at 9:30 AM
sg.finance.yahoo.com logoProcessa Pharmaceuticals to Participate in Upcoming Investor Conferences - Update
sg.finance.yahoo.com - September 16 at 11:10 AM
nasdaq.com logoProcessa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans
nasdaq.com - September 1 at 6:03 PM
finance.yahoo.com logoCompanies Like Processa Pharmaceuticals (NASDAQ:PCSA) Are In A Position To Invest In Growth
finance.yahoo.com - August 20 at 6:02 PM
finance.yahoo.com logoProcessa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update
finance.yahoo.com - August 12 at 8:38 PM
ca.finance.yahoo.com logoOcuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update
ca.finance.yahoo.com - August 12 at 10:37 AM
Get Processa Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:PCSA) was last updated on 2/2/2023 by MarketBeat.com Staff